jCyte’s stem cell therapy, jCell, was granted orphan drug designation by both the FDA and the European Medicines Agency, making the company eligible for certain patent protections, tax breaks, and grant funding. jCell was accepted into the competitive Therapeutics for Rare and Neglected Diseases (TRND) program at the NIH National Center for Advancing Translational Sciences (NCATS).
Integra Devices enables the manufacture of integrated, microscopic 3D structures that sense things, move things, and modify radio waves to make possible a new Internet of Things (IoT) and 5G wireless applications. The 10-employee company is housed at two incubators, Calit2 and EvoNexus.
PhageTech aims to revolutionize and simplify disease diagnosis by providing actionable, molecular insight to physicians within minutes at the point-of-care.The company was cofounded by Richard Henson, and UCI chemistry professors Gregory Weiss and Reginald Penner. PhageTech’s patented BioSensor™ technology was developed during 10 years of NIH and NSF-funded research at UCI. The company’s electrochemical biosensor platform can perform simple, low cost diagnostic testing directly from body fluids such as urine and blood without complex sample preparation or reagents, and can be used by minimally-trained medical staff.
Glaucoma is a general grouping of eye diseases that impact the optic nerve, resulting in progressive vision loss. According to the NIH National Eye Institute, currently, over 2.7 million Americans suffer from glaucoma, and approximately 11 million are projected to be afflicted by 2050. For many years, clinicians have struggled to find an efficacious treatment for glaucoma. To date, first-line drugs have had limited effectiveness due to progression of the disease or low patient compliance, and conventional surgical methods lacked the efficacy to produce a long-term cure. In the late 1990s, researchers began thinking about non-traditional approaches for
Professor and inventor Michael Demetriou has been studying immune-related diseases and cancers long before founding GlyTR Therapeutics in 2015. Prof. Demetriou’s research focuses on aberrant protein glycosylation that occurs in diseased cells. Glycosylation, the addition of sugars or glycans to proteins and other biomolecules, is an important method cells use to define the structure, function, and transportation of the molecule.